On December 6th, MD Anderson Cancer Center and NIH announced that they will be funding a clinical trial that will combine two Mesoblast technologies:
- Mesenchymal Precursor Cell (MPC)-based expansion
- Ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplantation in cancer patients
The purpose of the trial is to provide clinical data to indicate whether these technologies can interact synergistically to promote faster cord blood HSC engraftment for bone marrow transplant patients. [Read more…]